Welcome

Developing a new treatment for sepsis and multiple organ failure

At Thrombologic, we’re working to prevent sepsis and multiple organ failure from claiming the lives of intensive care patients in hospitals all over the world. Thanks to a new understanding of the pathogenesis that causes multiple organ failure, we hope to realize our mission in the foreseeable future. We believe sepsis can be treated within the framework of existing therapies, enabling us to take a shorter path when developing a treatment that could save thousands of lives every year.

Treating sepsis in intensive care

Sepsis (in layman’s terms, blood poisoning) is a globally occurring medical condition that complicates other conditions, such as severe infection. Characterized by systemic inflammation and widespread tissue injury, sepsis leads to multiple organ failure in roughly one in three cases, and death in 50 percent of patients within six months of diagnosis. In the US, 35 percent of patients experience severe sepsis during their intensive care admission – putting intensive care units under considerable strain.

We hope that our new therapy can significantly improve treatment for critically ill patients with sepsis.

§ Find out more about Thrombologic’s proposed sepsis therapy

§ Read more about sepsis on the Surviving Sepsis Campaign website